Misplaced Pages

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

Turkovac (pronunciation: ) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.

Clinical trials

In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.

In February 2021, Turkovac started on phase II trials with 250 participants in Turkey.

In June 2021, Turkovac started on phase III trials with 40,800 participants in Turkey. As of 2023 phase III trials continue.

Authorization

On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed. On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.

References

1. "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
2. Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
3. Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine Erucov-Vac" at ClinicalTrials.gov
4. Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated Erucov-Vac Compared With Placebo in COVID-19 " at ClinicalTrials.gov
5. "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (Turkovac) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
6. "ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 16 January 2024.
7. "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.
8. "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.

• Medicine
• Viruses
• COVID-19

This article about COVID-19 vaccines is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This article about vaccines or vaccination is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Turkish COVID-19 vaccines
• Drugs not assigned an ATC code
• Products introduced in 2020
• Inactivated vaccines
• COVID-19 vaccine stubs
• Vaccine stubs